OraSure Technologies Inc (OSUR)
OraSure Technologies, Inc. is a healthcare company focused on diagnostic products and specimen collection devices. Its portfolio includes rapid tests and self-tests for HIV, hepatitis C, syphilis, Ebola, COVID-19, and sickle cell screening, along with oral fluid and other sample collection tools. The company also sells drug testing systems, immunoassay products, saliva alcohol tests, and products used in genomic and microbiome sample collection under brands such as Oragene, ORAcollect, OMNIgene, and Colli-Pee. In addition, OraSure develops molecular self-testing products for chlamydia trachomatis and neisseria gonorrhoeae. The company serves customers in clinical laboratories, hospitals, clinics, community organizations, public health agencies, distributors, physicians’ offices, and other commercial and industrial settings across the United States and international markets. OraSure Technologies was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-OSUR
|
$4.13
|
9.5% Upside
|
Fair
|
$5
|
32.5% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-3.5x
|
0.8x
|
2.3x
|
265.1 M
|
70.73 M
|
4.6%
|
88.2%
|
1.9
|
—
|
63.8%
|
